{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:46:08Z","timestamp":1778510768815,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijantimicag.2021.106458","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T12:10:46Z","timestamp":1635163846000},"page":"106458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["New options for bloodstream infections caused by colistin\u2010 or ceftazidime\/avibactam\u2010resistant Klebsiella pneumoniae"],"prefix":"10.1016","volume":"58","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2021.106458_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00355-19","article-title":"The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program","volume":"63","author":"Diekema","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13756-019-0499-1","article-title":"Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, Southwest China, 2012\u20132017","volume":"8","author":"Yang","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0003","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","article-title":"Resistance to ceftazidime\u2013avibactam and underlying mechanisms","volume":"22","author":"Wang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12879-014-0659-0","article-title":"Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","article-title":"Multiplex PCR for detection of acquired carbapenemase genes","volume":"70","author":"Poirel","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijantimicag.2017.03.011","article-title":"In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae","volume":"50","author":"Yu","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime\u2013avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"COMBACTE-CARE Consortium\/REJUVENATE Study Group. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0011","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/AAC.01713-15","article-title":"Meropenem\u2013RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0012","doi-asserted-by":"crossref","first-page":"e01411","DOI":"10.1128\/AAC.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel \u03b2-lactamase inhibitor, dosed in combination with imipenem\u2013cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0014","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1592\/phco.23.8.988.32878","article-title":"Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion","volume":"23","author":"Dandekar","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106178","article-title":"In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae","volume":"56","author":"Clark","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime\u2013avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem\u2013vaborbactam versus ceftazidime\u2013avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0019","article-title":"Activities of imipenem\u2013relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","author":"Yang","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2021.106458_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime\u2013avibactam or meropenem\u2013vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921012917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857921012917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:40:55Z","timestamp":1760377255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857921012917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0924857921012917"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106458","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New options for bloodstream infections caused by colistin\u2010 or ceftazidime\/avibactam\u2010resistant Klebsiella pneumoniae","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106458"}}